Amplia Therapeutics Ltd has released a press release.
Amplia Successfully Completes Institutional Offer
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Capital Raise Presentation
- Amplia to Raise up to $13m for ACCENT and US Trials
- Interim Data From Accent Pancreatic Cancer Trial
- Sixth Confirmed Response in Pancreatic Cancer Trial
- FDA Fast Track Designation for Narmafotinib
Later from Amplia Therapeutics
- Security Class Suspension from Quotation
- App 4D and Financial Report Half Year ended 30 Sep 2024
- Security Class Reinstatement to Quotation - ATXOA
- Completion of Recruitment of ACCENT Trial
- ACCENT Trial Achieves Superiority over Chemotherapy Alone
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics